WO2021143001A1 - 一种将间充质干细胞诱导分化为胰岛细胞的诱导剂 - Google Patents

一种将间充质干细胞诱导分化为胰岛细胞的诱导剂 Download PDF

Info

Publication number
WO2021143001A1
WO2021143001A1 PCT/CN2020/092082 CN2020092082W WO2021143001A1 WO 2021143001 A1 WO2021143001 A1 WO 2021143001A1 CN 2020092082 W CN2020092082 W CN 2020092082W WO 2021143001 A1 WO2021143001 A1 WO 2021143001A1
Authority
WO
WIPO (PCT)
Prior art keywords
inducer
cells
mesenchymal stem
stem cells
induction
Prior art date
Application number
PCT/CN2020/092082
Other languages
English (en)
French (fr)
Inventor
张炳强
陈梦梦
李翠翠
王二朴
王福斌
邹伟
付学奇
刘翠娟
Original Assignee
青岛瑞思德生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 青岛瑞思德生物科技有限公司 filed Critical 青岛瑞思德生物科技有限公司
Priority to KR1020207038051A priority Critical patent/KR102459759B1/ko
Priority to US17/259,462 priority patent/US20210363489A1/en
Priority to EP20838869.4A priority patent/EP4092106A4/en
Priority to JP2020573503A priority patent/JP7087119B2/ja
Publication of WO2021143001A1 publication Critical patent/WO2021143001A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/37—Parathyroid hormone [PTH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood

Definitions

  • the invention belongs to the field of biomedicine, and relates to an inducer for inducing differentiation of mesenchymal stem cells into pancreatic islet cells.
  • Diabetes diabetes (diabetes mellitus, DM) is an endocrine and metabolic disease characterized by disorders of glucose and lipid metabolism. According to forecasts published by the World Health Organization and the International Diabetes Federation, by 2030, there will be 370 million people with diabetes worldwide. At present, there are more than 45 million DM patients in my country, ranking second only to India. Although the etiology is different, they are all manifested as defects in the number and function of pancreatic islet cells, and ultimately require the use of insulin for treatment. Although due to the application of insulin, especially in recent years, some progress has been made in insulin dosage forms and administration routes, but practice has proved that exogenous insulin cannot perfectly control blood sugar and constantly maintain normal blood sugar like the human body secretes insulin.
  • Cell replacement therapy is an important method for the treatment of diabetes. It is an effective method that is closer to the physiological way, which can realize continuous monitoring and fine adjustment of blood sugar.
  • the implantation of islet cells through the hepatic portal vein has also achieved some curative effects in the treatment of diabetes.
  • islet cell transplantation faces two problems: insufficient donor sources and severe immune rejection.
  • Stem cells as a kind of self-renewing and multi-differentiated cells, can differentiate into functional pancreatic islet cells under certain conditions, so they can be used as a new source of pancreatic islet cells.
  • pancreatic islet cells There are currently three ways to obtain pancreatic islet cells from stem cell differentiation: 1. Embryonic stem cell differentiation; 2. Pancreatic islet stem cell or islet precursor cell differentiation; 3. Adult stem cell differentiation. Because embryonic stem cells are ethically controversial and it is difficult to obtain islet stem cells, adult stem cells have a wide range of sources without ethical controversy and can be used as a source of islet cells.
  • the current stem cell induction methods mainly include in vitro induction, gene modification, protein transduction, and tissue microenvironment induction.
  • In vitro induction uses a combination of different stimulating factors to induce differentiation of stem cells into target cells. Different laboratories have different conditions for inducing differentiation, the mechanism of inducing differentiation is not clear, the efficiency of inducing differentiation is low, the secretion capacity of pancreatic islets is only about 1% of normal islets, and the induction process is complicated, the induction time is long, the number of cells obtained is small, and the function is low.
  • the purpose of the present invention is to solve the above-mentioned problems in the prior art and provide an inducer for inducing mesenchymal stem cells to differentiate into pancreatic islet cells.
  • Each component is safe and non-toxic, and requires fewer steps and short time for inducing differentiation. High induction efficiency.
  • an inducer for inducing mesenchymal stem cells to differentiate into pancreatic islet cells which is composed of the following components: GLP-1, parathyroid hormone, acetaminophen, ray Paamycin, icariin, trametinib, EPO and VEGF.
  • the mass concentration ratio of each component of the inducer is: GLP-1 20-40mg/L, parathyroid hormone 6-12mg/L, acetaminophen 2-8mg/L, rapamycin 2-8mg /L, icariin 2-8mg/L, trametinib 0.3-0.6mg/L, EPO 2-4ug/L, VEGF 2-4ug/L.
  • the mass concentration ratio of each component of the inducer is: GLP-1 30mg/L, parathyroid hormone 9mg/L, acetaminophen 5mg/L, rapamycin 5mg/L, epidermis Huoside 5mg/L, trametinib 0.4mg/L, EPO 3ug/L, VEGF 3ug/L.
  • Short induction time current literature generally requires more than 10 days for induction, and only 5 days for the induction agent of the present invention
  • Using the inducer of the present invention to induce mesenchymal stem cells into pancreatic islet cells has high induction and differentiation efficiency;
  • mesenchymal stem cells After the mesenchymal stem cells are induced to differentiate into islet cells, there is no rejection after transplantation, no ethical issues, high safety, and broad clinical application prospects.
  • Figure 1 shows the reaction of dithizone staining, showing that the induced group of the invention is red after dithizone staining.
  • Example 1 The inducer of this example for inducing mesenchymal stem cells into pancreatic islet cells is composed of the following components in a mass concentration ratio: GLP-1 30mg/L, parathyroid hormone 9mg/L, acetaminophen 5mg/L, rapamycin 5mg/L, icariin 5mg/L, trametinib 0.4mg/L, EPO 3ug/L, VEGF 3ug/L.
  • GLP-1 30mg/L
  • parathyroid hormone 9mg/L acetaminophen 5mg/L
  • rapamycin 5mg/L rapamycin 5mg/L
  • icariin 5mg/L trametinib 0.4mg/L
  • EPO 3ug/L VEGF 3ug/L
  • All components of the inducer of the present invention are commercially available products: human mesenchymal stem cell serum-free medium, brand LONZA, item number 00190632; GLP-1 (glucagon-like peptide 1), brand Sigma, item number scp0153; parathyroid gland Hormone, brand Sigma, article number P7036; Paracetamol, Shanghai Yiji Industrial Co., Ltd., article number Y903952; rapamycin, brand name TargetMol, article number T1537; Icariin, Shanghai Microcrystalline Biology, article number 489-32-7 ; Trimetinib, brand Meilun Bio, article number MB5401; EPO, brand PeproTech, article number CYT-201; VEGF, brand PeproTech, article number 96-100-20-2.
  • the inducer for inducing mesenchymal stem cells into pancreatic islet cells in this embodiment is composed of the following components with a mass concentration ratio: GLP-1 20mg/L, parathyroid hormone 6mg/L, and parathyroid phenol 2mg/L , Rapamycin 2mg/L, icariin 2mg/L, trametinib 0.3mg/L, EPO 2ug/L, VEGF 2ug/L.
  • the above-mentioned components are sequentially added to human mesenchymal stem cell serum-free medium (or DMEM+10% FBS) according to the mass concentration ratio, mixed well, and filtered and sterilized.
  • the inducer for inducing mesenchymal stem cells into pancreatic islet cells in this embodiment is composed of the following components in a mass concentration ratio: GLP-1 40mg/L, parathyroid hormone 12mg/L, and paracetamol 8mg/L , Rapamycin 8mg/L, icariin 8mg/L, trametinib 0.6mg/L, EPO 4ug/L, VEGF 4ug/L.
  • the human umbilical cord mesenchymal stem cells of the third passage were digested with 0.125% ⁇ 0.01% Trypsin-EDTA solution to collect the cells, prepare a cell suspension, count the density of viable cells on a cell counter, and adjust the density to 1 ⁇ 10 4 /cm 2 , and inoculate
  • a 24-well plate with a sterile cover glass treated with polylysine is placed in advance to prepare a cell climbing slide. When the cells reach close to 80% confluence, and then induce differentiation when they grow vigorously, see Table 1 for grouping.
  • Dithizone staining reaction Take the islet cells obtained after 5 days of induction in the above three groups (induction group 1 needs to induce differentiation for 10 days), remove the original medium, wash with PBS twice, and add 2ml PBS and 50ul each Incubate the working solution of dithizone at 37°C for 10 minutes, remove the staining solution, wash twice with PBS, observe the staining of the cells and take pictures. The results are shown in the figure.
  • the dithizone staining of the two induction groups is red (as shown in Figure 1), which is a positive reaction, and the control group is negative.
  • the ELISA kit detects whether the pancreatic islet-like cells induced by the inducer of the present invention have pancreatic islet cell function: this detection process directly follows the "C-peptide ELISA assays" standard process provided by Mercodia. In the final result, C-peptide was detected, indicating that the islet-like cells obtained by the inducer of the present invention to induce differentiation can secrete insulin.
  • Glucose stimulation experiment Pick 100 pancreatic islet cell clusters (50-150um) induced to differentiate for 5 days with the inducer of the present invention and put them in a 1.5ml centrifuge tube, wash them twice with PBS, and add 1ml sugar-free DMEM to pre-culture for 3 ⁇ 6h, then incubate in 300ul DMEM containing 5.6mmol/L glucose and 16.7mmol/L glucose for 2h successively, collect the supernatant, detect the secretion of insulin in the supernatant stimulated by different concentrations of glucose by ELISA, and control the cell supernatant Insulin can hardly be detected in the cell, and the induced pancreatic islet cell group secreted a small amount under the stimulation of 5.6mmol/L glucose.
  • pancreatic islet cell mass is sensitive to glucose stimulation after induction, and its insulin secretion is regulated by the external environment.

Abstract

提供了一种将间充质干细胞诱导分化为胰岛细胞的诱导剂，该诱导剂由以下组分组成：GLP-1、甲状旁腺激素、对乙酰氨基酚、雷帕霉素、淫羊藿苷、曲美替尼、EPO和VEGF。该诱导剂各成分均安全无毒性，诱导分化所需步骤少、时间短，诱导效率高。

Description

一种将间充质干细胞诱导分化为胰岛细胞的诱导剂 技术领域
本发明属于生物医学领域，涉及一种将间充质干细胞诱导分化为胰岛细胞的诱导剂。
背景技术
糖尿病(diabetes mellitus，DM)是一种以糖脂代谢紊乱为主要特征的内分泌代谢性疾病。根据世界卫生组织和国际糖尿病联盟公布的预测，到2030年，全球糖尿病患者将达3.7亿。目前我国DM患者已超过4500万，仅次于印度居第二位。尽管其病因不同，但都表现为胰岛细胞数量及功能的缺陷，最终都需要使用胰岛素进行治疗。尽管由于胰岛素的应用，尤其是近年来在胰岛素剂型以及给药途径等方面均取得了一些进展，但实践证明外源性胰岛素并不能像人体自身分泌胰岛素那样完美地控制血糖并恒定维持血糖正常。细胞替代疗法是治疗糖尿病的重要方法，是一种更接近生理方式的有效方法，可实现对血糖进行持续监测和精细调节。近些年，经肝门静脉植入胰岛细胞治疗糖尿病也获得了一些疗效，但胰岛细胞移植面临着两个难题：供体来源不足及严重的免疫排斥反应。
干细胞作为一种具有自我更新及多向分化的细胞，在一定条件下可分化为具有功能性的胰岛细胞，因此可作为胰岛细胞的全新来源。目前由干细胞分化获得胰岛细胞有三种途径：1、胚胎干细胞分化；2、胰岛干细胞或胰岛前体细胞分化；3、成体干细胞分化。由于胚胎干细胞具有伦理争议，且很难获得胰岛干细胞，而成体干细胞来源广泛，无伦理争议，可作为胰岛细胞的来源。
目前的干细胞诱导方式主要有体外诱导、基因修饰、蛋白转导与组织微环境诱导，其中体外诱导是采用不同刺激因子组合，将干细胞诱导分化为目的细胞。各实验室诱导分化条件各异，诱导分化机制尚不明确，诱导分化效率低，胰岛分泌能力仅为正常胰岛1％左右，且诱导过程复杂，诱导时间长，所得细胞数量少，功能低。
发明内容
本发明的目的是为了解决现有技术中存在的上述问题，提供一种将间充质干细胞诱导分化成胰岛细胞的诱导剂，各成分均安全无毒性，诱导分化所需步骤少、时间短，诱导效率高。
为实现上述目的，本发明采用的技术方案是：一种将间充质干细胞诱导分化为胰岛细胞的诱导剂，由以下组分组成：GLP-1、甲状旁腺激素、对乙酰氨基酚、雷帕霉素、淫羊藿苷、曲美替尼、EPO和VEGF。
所述诱导剂各组分的质量浓度配比为：GLP-1 20-40mg/L、甲状旁腺激素6-12mg/L、对乙酰氨基酚2-8mg/L、雷帕霉素2-8mg/L、淫羊藿苷2-8mg/L、曲美替尼0.3-0.6mg/L、EPO 2-4ug/L、VEGF 2-4ug/L。
优选的，所述诱导剂各组分的质量浓度配比为：GLP-1 30mg/L、甲状旁腺激素9mg/L、对乙酰氨基酚5mg/L、雷帕霉素5mg/L、淫羊藿苷5mg/L、曲美替尼0.4mg/L、EPO 3ug/L、VEGF 3ug/L。
本发明的一种将间充质干细胞诱导分化为胰岛细胞的诱导剂，具有以下优势：
1、无需基因转染，故无基因改变和癌症风险；
2、诱导步骤少：当前文献报道的方法以两步法或者三步法为主，采用本发明的诱导剂仅需要一步；
3、诱导时间短：当前文献一般诱导需要10天以上，采用本发明的诱导剂仅需要5天；
4、采用本发明的诱导剂将间充质干细胞诱导成胰岛细胞诱导分化效率高；
5、本发明的诱导剂，各成分均安全无毒性；
6、间充质干细胞诱导分化为胰岛细胞后，移植后无排斥，无伦理问题，安全性高，具有广阔的临床应用前景。
附图说明
图1是双硫腙染色反应，示本发明诱导组双硫腙染色后呈红色。
具体实施方式
实施例1本实施例的将间充质干细胞诱导成胰岛细胞的诱导剂，由以下质量浓度配比的组分组成：GLP-1 30mg/L、甲状旁腺激素9mg/L、对乙酰氨基酚5mg/L、雷帕霉素5mg/L、淫羊藿苷5mg/L、曲美替尼0.4mg/L、EPO 3ug/L、VEGF 3ug/L。将上述组分按质量浓度配比依次加入人间充质干细胞无血清培养基(或者DMEM+10％FBS或者市售的其他类型间充质干细胞培养基)，混匀，过滤除菌即可。
本发明的诱导剂各成分均为市售产品：人间充质干细胞无血清培养基，品牌LONZA，货号00190632；GLP-1(胰高血糖素样肽1)，品牌Sigma,货号scp0153；甲状旁腺激素，品牌Sigma，货号P7036；对乙酰氨基酚，上海一基实业有限公司，货号Y903952；雷帕霉素，品牌TargetMol，货号T1537；淫羊藿苷，上海微晶生物,货号489-32-7；曲美替尼，品牌美仑生物，货号MB5401；EPO，品牌PeproTech，货号CYT-201；VEGF，品牌PeproTech，货号96-100-20-2。
实施例2
本实施例的将间充质干细胞诱导成胰岛细胞的诱导剂，由以下质量浓度配比的组分组成：GLP-1 20mg/L、甲状旁腺激素6mg/L、对乙酰氨基酚2mg/L、雷帕霉素2mg/L、淫羊藿苷2mg/L、曲美替尼0.3mg/L、EPO 2ug/L、VEGF 2ug/L。将上述组分按质量浓度配比依次加入人间充质干细胞无血清培养基(或者DMEM+10％FBS)，混匀，过滤除菌即可。
实施例3
本实施例的将间充质干细胞诱导成胰岛细胞的诱导剂，由以下质量浓度配比的组分组成：GLP-1 40mg/L、甲状旁腺激素12mg/L、对乙酰氨基酚8mg/L、雷帕霉素8mg/L、淫羊藿苷8mg/L、曲美替尼0.6mg/L、EPO 4ug/L、VEGF 4ug/L。将上述组分按质量浓度配比依次加入人间充质干细胞无血清培养基(或者DMEM+10％FBS)，混匀，过滤除菌即可。
实施例4
以人脐带间充质干细胞为例说明本发明诱导剂效果
一、诱导人脐带间充质干细胞分化为胰岛细胞
传3代的人脐带间充质干细胞，0.125％～0.01％Trypsin-EDTA溶液消化收集细胞，制备细胞悬液，细胞计数板计数活细胞密度，并调整密度1×10 4/cm 2，接种于事先放置有经多聚赖氨酸处理的消毒盖玻片的24孔板内，制备细胞爬片。待细胞达接近80％融合，生长旺盛时再进行诱导分化，分组见表1。
表1诱导分组
Figure PCTCN2020092082-appb-000001
Figure PCTCN2020092082-appb-000002
二、诱导后胰岛细胞的鉴定
(一)、双硫腙染色反应：分别取以上三组诱导5天后获得的胰岛细胞(其中诱导组1需要诱导分化10天)，移出原培养基，PBS洗2次，各加入2ml PBS和50ul双硫腙工作液，37℃孵育10min,移出染色液，PBS洗涤两次，观察细胞着色情况并拍照。结果如图所示，两个诱导组双硫腙染色后呈红色(如图1所示)，为阳性反应，对照组为阴性。
(二)化学发光免疫分析法检测胰岛素水平：分别取以上三组诱导5天后(其中诱导组1需要诱导分化10天)细胞培养上清，检测胰岛素含量，诱导组2的细胞分泌胰岛素浓度为518.7mU/L，远高于诱导组1的细胞分泌胰岛素浓度212.1mU/L，而空白对照组检测胰岛素浓度为零，说明本发明的诱导剂可以显著提高诱导效率。
(三)ELISA试剂盒检测用本发明诱导剂诱导获得的胰岛样细胞是否具有胰岛细胞功能：这一检测过程直接按照Mercodia公司所提供的“C-peptide ELISA assays”标准过程操作。最终结果检测出C-肽，说明经本发明的诱导剂诱导分化获得的胰岛样细胞能够分泌胰岛素。
(四)葡萄糖刺激实验：挑取100个本发明诱导剂诱导分化5天的胰岛细胞团(50～150um)至1.5ml离心管中，用PBS清洗2遍，加入1ml无糖DMEM预培养3～6h，然后以300ul含有5.6mmol/L葡萄糖、16.7mmol/L葡萄糖的DMEM依次培养2h，收集上清液，用ELISA法检测上清中不同浓度葡萄糖刺激下胰岛素的分泌量，对照组细胞上清中几乎检测不到胰岛素，而经诱导的胰岛细胞团在5.6mmol/L葡萄糖刺激下有少量分泌，经16.7mmol/L葡萄糖孵育2h后，胰岛素分泌量明显升高(P<0.001)，约为低糖条件下的2倍，由此结果可知，诱导后胰岛细胞团对葡萄糖刺激敏感，其胰岛素的分泌受外环境的调控。
(五)体内移植实验：首先制作糖尿病大鼠模型。取成年Wistar大鼠，雌雄不限，体重约180～200g。按照70mg/kg剂量给每只大鼠腹腔注射链脲霉素。链脲霉素粉剂用0.1M柠檬酸缓冲液(PH＝4.5)配成液体使用，现配现用。当大鼠血糖升高(≥16.7mmol/L)且稳定一周，表明糖尿病模型已经建成。无菌条件下，向糖尿病大鼠肾包囊下或者肝门脉小分支注入300个本发明的诱导剂诱导得到的 胰岛样细胞团(50～150um)。术后，定期观测血糖情况。结果：糖尿病大鼠在植入细胞3天后血糖平均下降7.3mmol/L。表明采用本发明诱导剂诱导分化获得的胰岛细胞团具有显著的降血糖作用。

Claims (3)

  1. 一种将间充质干细胞诱导分化为胰岛细胞的诱导剂，其特征为，由以下组分组成：GLP-1、甲状旁腺激素、对乙酰氨基酚、雷帕霉素、淫羊藿苷、曲美替尼、EPO和VEGF。
  2. 根据权利要求1所述的一种将间充质干细胞诱导分化为胰岛细胞的诱导剂，其特征在于：各组分的质量浓度配比为：GLP-1 20-40mg/L、甲状旁腺激素6-12mg/L、对乙酰氨基酚2-8mg/L、雷帕霉素2-8mg/L、淫羊藿苷2-8mg/L、曲美替尼0.3-0.6mg/L、EPO 2-4ug/L、VEGF 2-4ug/L。
  3. 根据权利要求2所述的一种将间充质干细胞诱导分化为胰岛细胞的诱导剂，其特征在于：各组分的质量浓度配比为：GLP-1 30mg/L、甲状旁腺激素9mg/L、对乙酰氨基酚5mg/L、雷帕霉素5mg/L、淫羊藿苷5mg/L、曲美替尼0.4mg/L、EPO 3ug/L、VEGF 3ug/L。
PCT/CN2020/092082 2020-01-13 2020-05-25 一种将间充质干细胞诱导分化为胰岛细胞的诱导剂 WO2021143001A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1020207038051A KR102459759B1 (ko) 2020-01-13 2020-05-25 중간엽 줄기세포를 도세포로 유도 분화하는 유도제
US17/259,462 US20210363489A1 (en) 2020-01-13 2020-05-25 An inducer for inducing a mesenchymal stem cell to differentiate into an islet cell
EP20838869.4A EP4092106A4 (en) 2020-01-13 2020-05-25 INDUCER FOR INDUCING MESENCHYMAL STEM CELLS TO DIFFERENTIATE INTO ISLAND CELLS
JP2020573503A JP7087119B2 (ja) 2020-01-13 2020-05-25 間葉系幹細胞から膵島細胞への誘導分化用の誘導剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010032047.1A CN113106054B (zh) 2020-01-13 2020-01-13 一种将间充质干细胞诱导分化为胰岛细胞的诱导剂
CN202010032047.1 2020-01-13

Publications (1)

Publication Number Publication Date
WO2021143001A1 true WO2021143001A1 (zh) 2021-07-22

Family

ID=76708861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/092082 WO2021143001A1 (zh) 2020-01-13 2020-05-25 一种将间充质干细胞诱导分化为胰岛细胞的诱导剂

Country Status (6)

Country Link
US (1) US20210363489A1 (zh)
EP (1) EP4092106A4 (zh)
JP (1) JP7087119B2 (zh)
KR (1) KR102459759B1 (zh)
CN (1) CN113106054B (zh)
WO (1) WO2021143001A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116574670B (zh) * 2023-05-12 2024-01-02 中科中銮生物科技(广东)有限公司 一种诱导间充质干细胞向胰岛样细胞分化的方法及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103756954A (zh) * 2014-01-22 2014-04-30 青岛中天干细胞工程有限公司 一种将人脂肪间充质干细胞诱导成胰岛素分泌细胞的诱导剂、诱导培养基及方法
CN104845932A (zh) * 2015-04-29 2015-08-19 天津中医药大学 淫羊藿苷的新用途
CN105132369A (zh) * 2015-08-25 2015-12-09 北京瑞思德生物医学研究院 一种将间充质干细胞转化为睾酮分泌细胞的诱导剂及诱导培养基
KR20160022758A (ko) * 2014-08-19 2016-03-02 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법
CN106190965A (zh) * 2016-07-19 2016-12-07 袁肇斌 一种骨髓间充质干细胞体外培养液及培养扩增方法
CN107372464A (zh) * 2017-08-21 2017-11-24 成都康景生物科技有限公司 一种维持间充质干细胞活性的运输保存液与制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2004696A3 (cs) * 2001-11-09 2005-02-16 Artecel Sciences, Inc. Endokrinní pankreatická diferenciace buněk stromatu odvozených z adipózní tkáně a její použití
KR101089591B1 (ko) * 2001-12-07 2011-12-05 제론 코포레이션 인간 배아 줄기세포 유래의 섬세포
US20050208029A1 (en) * 2002-04-17 2005-09-22 Akihiro Umezawa Method of forming pancreatic beta cells from mesenchymal cells
DE60326002D1 (de) * 2002-10-22 2009-03-12 Waratah Pharmaceuticals Inc Behandlung von diabetes.
WO2005086860A2 (en) * 2004-03-09 2005-09-22 Gang Xu Methods for generating insulin-producing cells
US20060153894A1 (en) * 2004-06-30 2006-07-13 Ragae Ghabrial Multi-compartment delivery system
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
CN107574142B (zh) * 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
TWI434931B (zh) * 2010-12-03 2014-04-21 Yung Kai Lin 細胞培養基之營養添加劑
ITMI20110780A1 (it) * 2011-05-06 2012-11-07 Euroclone Spa Terreno di coltura per differenziare cellule staminali in cellule beta
CN105062970B (zh) * 2015-08-25 2017-12-29 青岛瑞思科生物科技有限公司 一种将间充质干细胞诱导成神经细胞的诱导剂及诱导分化完全培养基
CN108865989A (zh) * 2018-07-23 2018-11-23 吉林济惠生物科技有限公司 一种脐带间充质干细胞的培养基

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103756954A (zh) * 2014-01-22 2014-04-30 青岛中天干细胞工程有限公司 一种将人脂肪间充质干细胞诱导成胰岛素分泌细胞的诱导剂、诱导培养基及方法
KR20160022758A (ko) * 2014-08-19 2016-03-02 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법
CN104845932A (zh) * 2015-04-29 2015-08-19 天津中医药大学 淫羊藿苷的新用途
CN105132369A (zh) * 2015-08-25 2015-12-09 北京瑞思德生物医学研究院 一种将间充质干细胞转化为睾酮分泌细胞的诱导剂及诱导培养基
CN106190965A (zh) * 2016-07-19 2016-12-07 袁肇斌 一种骨髓间充质干细胞体外培养液及培养扩增方法
CN107372464A (zh) * 2017-08-21 2017-11-24 成都康景生物科技有限公司 一种维持间充质干细胞活性的运输保存液与制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EL-ASFAR RANA K.; KAMAL MOHAMED M.; ABD EL-RAZEK RANIA S.; EL-DEMERDASH EBTEHAL; EL-MESALLAMY HALA O.: "Obestatin can potentially differentiate Wharton's jelly mesenchymal stem cells into insulin-producing cells", CELL AND TISSUE RESEARCH, vol. 372, no. 1, 20 November 2017 (2017-11-20), pages 91 - 98, XP036463368, ISSN: 0302-766X, DOI: 10.1007/s00441-017-2725-6 *
JIAHAI-YAN,XIAO ZHU,LONG YANG: "Differentiation of Human Bone Marrow Mesenchymai Stem Cells(hBMSCs) Into Insulin-Secreting Cells", CHINESE JOURNAL OF DIABETES, vol. 17, no. 7, 20 July 2009 (2009-07-20), pages 505 - 509, XP055829629, ISSN: 1006-6187, DOI: 10.3969/j.issn.1006-6187.2009.07.007 *
See also references of EP4092106A4 *

Also Published As

Publication number Publication date
KR20210093750A (ko) 2021-07-28
CN113106054A (zh) 2021-07-13
EP4092106A4 (en) 2024-03-06
KR102459759B1 (ko) 2022-10-26
CN113106054B (zh) 2022-10-14
JP7087119B2 (ja) 2022-06-20
US20210363489A1 (en) 2021-11-25
EP4092106A1 (en) 2022-11-23
JP2022519794A (ja) 2022-03-25

Similar Documents

Publication Publication Date Title
ES2276392T3 (es) Crecimiento in vitro de islotes funcionales de langerhans y utilizaciones in vivo de los mismos.
KR101505382B1 (ko) 인간 배아 줄기 세포 및 그의 유도체를 포함하는 조성물, 그의 사용 방법 및 제조 방법
EP1401282A1 (en) Stem cell differentiation
WO2009116087A1 (en) Human adipose derived insulin making mesenchymal stem cells for treating diabetes mellitus
KR20100035637A (ko) 신부전 치료를 위한 선택적 세포 치료법
EA035360B1 (ru) Способы трансдифференцировки и способы их использования
CN103756954A (zh) 一种将人脂肪间充质干细胞诱导成胰岛素分泌细胞的诱导剂、诱导培养基及方法
WO2021143001A1 (zh) 一种将间充质干细胞诱导分化为胰岛细胞的诱导剂
He et al. MSCs promote the development and improve the function of neonatal porcine islet grafts
CN114381395B (zh) 一种植物乳杆菌zjufn1及其应用
TW201005091A (en) Cell culture method and application thereof
Luo et al. NLRP3 downregulation enhances engraftment and functionality of adipose-derived stem cells to alleviate erectile dysfunction in diabetic rats
Holzer et al. Autologous transplantation of porcine myogenic precursor cells in skeletal muscle
CN116574670B (zh) 一种诱导间充质干细胞向胰岛样细胞分化的方法及其用途
CN110917217B (zh) 肌肉干细胞在制备抗炎药物中的应用
JP2016008198A (ja) 間質性膀胱炎の治療
US8394629B2 (en) Use of vinca alkaloids and salts thereof
US8372641B2 (en) Marrow stem cell and pancreatic β cell fusion cell useful for the treatment of diabetes
CN102441159B (zh) 一种人类多肽在制备免疫调节剂中的应用
US20230097931A1 (en) Method for treating chronic graft versus host disease
KR101177273B1 (ko) 췌도세포의 배양시 그의 생존률 또는 기능을 증진시키는방법
CN111870689A (zh) 一种纳豆激酶在治疗骨质疏松药物中的应用
AU2008265973A1 (en) Methods of restoration of erectile function
CN109125348A (zh) 脐带充质干细胞联合维生素d在治疗糖尿病药物中的应用
CN115518077A (zh) 一种治疗炎症性肠病的细胞药物

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020573503

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20838869

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020838869

Country of ref document: EP

Effective date: 20220816